Bridge Biotherapeutics Inc. has signed an exclusive option-to-license agreement for Cellionbiomed Inc.’s preclinical ion channel modulator, BBT-301, thus adding a second idiopathic pulmonary fibrosis (IPF) candidate to its fibrotic diseases portfolio. The company hopes to enter the clinic with the drug in the U.S. by the end of 2022.
Nec Corp. has acquired all of Vaximm AG’s neoantigen program assets. Tokyo-based Nec will conduct the acquisition via its subsidiary, Nec Oncoimmunity AS.
Three U.S.-listed China-based biopharmas were among five companies named this week by the U.S. SEC for reportedly failing to submit necessary accounting reports under the Holding Foreign Companies Accountable Act (HFCAA).
With the pandemic lingering across the world and more COVID-19 therapies becoming available and in demand, the opportunity for counterfeits is growing.
Australians with mantle cell lymphoma (MCL) will now have subsidized access to Beigene Ltd.’s BTK inhibitor, Brukinsa (zanubrutinib), as of March 1, marking the company’s first drug to be listed on Australia’s Prescription Benefits Scheme (PBS).
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Chimeric, Eucure, Gan & Lee, Geovax Labs, Incannex, Kintor, Moderna, Noxopharm, Pfizer, Prestige, Recce, Taiwan Liposome, Telix, Transcenta.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Akeso, Altamira, Antengene, Bayer, Beigene, Biogen, Immunome, Immutep, Orion, Pharmazz, Samsung Bioepis, Sanbio, SCG Cell Therapy, Valneva.
RSS
